Atherosclerosis is the primary pathophysiological cause of heart disease and cerebrovascular disease. It is responsible for more than 20% of deaths worldwide each year. Treatments for atherosclerosis may include lifes...Atherosclerosis is the primary pathophysiological cause of heart disease and cerebrovascular disease. It is responsible for more than 20% of deaths worldwide each year. Treatments for atherosclerosis may include lifestyle changes, drugs, and medical procedures or surgery. There is a need for a rapid and effective treatment for this disease. In 1976, it was hypothesized that a multifunctional plasma delipidation process when applied to hyperlipidemic patients would lead to rapid regression of atherosclerosis. The procedure has now been applied to a variety of non-primates, primates and humans. In all models studied, large quantities of antiatherogenic lipoprotein particles were generated that led to the mechanisms of reverse cholesterol transport. Trends to regression and actual regression of atherosclerosis have now been reported using a specific plasma delipidation process consisting of lipid extraction from plasma with mixtures of butanol and ethers.展开更多
Background: Psoriasis is a chronic disease that can have significant effects on quality of life. Aim: To test whether the antineoplastic, antipathogenic plant derived secondary metabolites, solasodine glycosides, can ...Background: Psoriasis is a chronic disease that can have significant effects on quality of life. Aim: To test whether the antineoplastic, antipathogenic plant derived secondary metabolites, solasodine glycosides, can treat psoriasis. Case Presentation: We report a case of a 54-year-old French-Vietnamese male who presented with diagnosed erythematous scaly annular recalcitrant psoriasis scattered throughout his body. Method: After failing conventional treatment regimens for over 10 years the patient received a trial with a topical cream formulation PsorendBEC, containing solasodine glycosides, for his psoriasis. Result: Topical applications of PsorendBEC twice daily resulted in complete resolution of cutaneous lesions after 4 weeks of treatment with no recurrence post 1 year after therapy. Conclusion: Topical PsorendBEC therapy rapidly removes recalcitrant psoriasis with no apparent side effects.展开更多
文摘Atherosclerosis is the primary pathophysiological cause of heart disease and cerebrovascular disease. It is responsible for more than 20% of deaths worldwide each year. Treatments for atherosclerosis may include lifestyle changes, drugs, and medical procedures or surgery. There is a need for a rapid and effective treatment for this disease. In 1976, it was hypothesized that a multifunctional plasma delipidation process when applied to hyperlipidemic patients would lead to rapid regression of atherosclerosis. The procedure has now been applied to a variety of non-primates, primates and humans. In all models studied, large quantities of antiatherogenic lipoprotein particles were generated that led to the mechanisms of reverse cholesterol transport. Trends to regression and actual regression of atherosclerosis have now been reported using a specific plasma delipidation process consisting of lipid extraction from plasma with mixtures of butanol and ethers.
文摘Background: Psoriasis is a chronic disease that can have significant effects on quality of life. Aim: To test whether the antineoplastic, antipathogenic plant derived secondary metabolites, solasodine glycosides, can treat psoriasis. Case Presentation: We report a case of a 54-year-old French-Vietnamese male who presented with diagnosed erythematous scaly annular recalcitrant psoriasis scattered throughout his body. Method: After failing conventional treatment regimens for over 10 years the patient received a trial with a topical cream formulation PsorendBEC, containing solasodine glycosides, for his psoriasis. Result: Topical applications of PsorendBEC twice daily resulted in complete resolution of cutaneous lesions after 4 weeks of treatment with no recurrence post 1 year after therapy. Conclusion: Topical PsorendBEC therapy rapidly removes recalcitrant psoriasis with no apparent side effects.
